Ministry of Health and Welfare Selects Six Consortiums for 'AX-Sprint' AI Medical Device Commercialization
Collaboration Among Government, Developers, and Medical Institutions
Comprehensive Support from Clinical Validation to Market Entry
The government has selected six consortiums and is launching full-scale support to expedite the clinical introduction of domestic AI (artificial intelligence) medical devices. The plan is to support pilot testing and the accumulation of real-use data so that outstanding AI-applied medical devices in areas such as brain disease prediction, cancer diagnosis, and cardiovascular risk prediction can be fully embedded in clinical settings through collaboration between developers and healthcare institutions.
On August 4, the Ministry of Health and Welfare and the Korea Health Industry Development Institute held a kick-off meeting and project agreement signing ceremony for the “Support Program for the Rapid Commercialization of AI-Applied Products (Healthcare Sector, Digital Medical Devices)” and announced support measures for introducing top-tier AI medical devices into clinical practice.
Until now, even if outstanding AI-applied medical devices were developed and received approval from the Ministry of Food and Drug Safety in Korea, significant barriers persisted before these devices could be adopted by medical institutions and covered under the national health insurance reimbursement system—meaning it took a long time for patients to experience cutting-edge medical technology firsthand. To address this, the government has launched the current project aiming to support on-site application and early commercialization of AI-based digital medical devices that face significant market-entry hurdles.
This project provides support for real-world clinical verification, real-use data accumulation, and marketing activities for AI-applied products through cooperation between developers and healthcare institutions. Six field-specific consortiums, whose solutions have high public impact and strong demand in clinical practice, have been selected in the final round.
By domain: In the area of brain diseases, the JLK consortium will introduce AI for brain perfusion and infarction analysis to neurology departments of 22 hospitals, including Hallym University Sacred Heart Hospital and Seoul National University Bundang Hospital, to substantiate the effectiveness and economic value of outcome improvement in acute stroke patients. The Hurayons consortium, in partnership with neurology departments at three hospitals including Sinchon Severance Hospital, will clinically validate MRI-based Parkinson’s disease diagnosis support AI that helps reduce the need for unnecessary PET scans and increases diagnostic accuracy.
In the cancer diagnosis field, the Lunit consortium will deploy chest X-ray and breast cancer diagnosis support AI in 10 hospitals, including Seoul National University Hospital, Kangbuk Samsung Hospital, and Konkuk University Hospital, accumulating 250,000 real-use data cases and aiming for integration into the insurance reimbursement system. The Previanotics consortium will introduce real-time AI analysis solutions for gastroscopy to the gastroenterology departments of seven major hospitals, such as Seoul National University Hospital and Severance Hospital, to improve the accuracy of diagnosing precancerous gastric lesions and reduce unnecessary biopsies.
In the cardiovascular prediction field, the SynergyAI consortium will apply biosignal analysis AI to the cardiology departments of 15 university hospitals, including Seoul St. Mary’s Hospital and Korea University Guro Hospital, to clinically validate the predictive efficacy for arrhythmia risk. The Mediwhale consortium, in collaboration with Yonsei Severance Hospital and Hanyang University Guri Hospital, plans to demonstrate the safety and effectiveness of fundus-based cardiovascular risk assessment AI and promote the listing of reimbursement codes for cardiovascular risk assessment in patients with chronic diseases and pre-surgical patients.
About 60 people, including officials from the Ministry of Health and Welfare and the Korea Health Industry Development Institute, heads of the six leading companies, and principal investigators (PIs) representing the main participating hospitals, attended the kick-off meeting and agreement ceremony, reaffirming their commitment to collaboration for the successful adoption of AI medical devices in clinical settings and patient benefit enhancement.
Seong Changhyeon, Director General of Health Industry Policy, stated, “This project will serve as a key primer to ensure AI digital medical devices transcend simple technological development and make tangible contributions to public health in real clinical environments. We will actively support the successful integration of top-tier AI medical devices in clinical practice and strive to spread the accumulated data and market entry experience industry-wide.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jung Younghoon, Planning Director of the Korea Health Industry Development Institute, emphasized, “It is imperative that the government, developers, and medical institutions cooperate organically to yield both substantive clinical outcomes and industrial achievements. Based on the institute’s expertise, we will reinforce field-driven management and offer tailored support.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.